DarioHealth Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports a material definitive agreement entered into by DarioHealth Corp. on February 28, 2022. The filing was submitted on March 4, 2022. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in New York, New York.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or debt metrics for a specific reporting period. However, it discloses the following financial terms related to the new agreement:
- Total Potential Consideration: Up to $30 million payable by Sanofi over the initial five-year term.
- Payment Structure: Includes an upfront payment, annual compensation for development costs, and contingent milestone payments based on net sales and enrollment rates.
- Revenue Sharing: DarioHealth will pay Sanofi a percentage of specified revenues ranging from the low double digits to the low twentieth percentile on qualifying sales. Revenue sharing in the thirtieth percentile applies to new solutions developed under the collaboration.
Material Changes
The primary material change is the entry into an exclusive preferred partner, co-promotion, development collaboration, and license agreement with Sanofi US Services, Inc. This agreement grants Sanofi a license to access certain Company data and grants the Company a license to certain Sanofi intellectual property for use in the United States.
Outlook, Risks, and Contingencies
Agreement Terms: The collaboration has an initial term of five years, renewable for an additional five years by mutual agreement.
Termination Risks: The agreement may be terminated under the following conditions:
- By either party for material breach, force majeure, or insolvency.
- By the Company if net sales requirements are not met.
- By either party for convenience with 60 days' notice, starting in the third year.
- By Sanofi if the Company fails to complete a development plan within nine months of the Effective Date or upon a change of control.
Management Commentary: The filing does not contain additional management commentary or forward-looking guidance beyond the terms of the agreement.
Key Facts for Investor Verification
- Verify the specific amount of the upfront payment included in the $30 million aggregate consideration.
- Confirm the specific net sales and enrollment rate milestones required to trigger contingent payments.
- Review the definition of "qualifying sales" and the specific revenue thresholds required to initiate revenue sharing payments to Sanofi.
- Monitor the Company's ability to complete the initial development plan within the nine-month window to avoid termination by Sanofi.